TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19455620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ambrisentan and Tadalafil
Study: 16335787
Drug: Garlic pearls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic pearls (GP) 250 mg per day for 2 months
Study: 11198728
Drug: Nisoldipine (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10-40 mg)
Study: 11198728
Drug: Amlodipine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5-10 mg)
Study: 8285333
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 2.5 mg
Study: 8285333
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia using diamorphine
Study: 3505874
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (completed personality inventory twice under standard directions)
Study: 28139161
Drug: Liposome-encapsulated Aloe
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome-encapsulated Aloe vera gel extract (AGE) for 5 weeks
Study: 23545908
Drug: Skin-lightening cream
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Skin-lightening cream (SLC) with 4% hydroquinone (HQ)
Study: 23545908
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream (TCC) with 4% hydroquinone (HQ), 0.05% tretinoin, and 0.01% fluocinolone acetonide
Study: 23545908
Drug: Skin-lightening cream
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Skin-lightening cream (SLC)
Study: 23545908
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream (TCC)
Study: 23545908
Drug: Both creams
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both creams
Study: 16991077
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of trivalent inactivated influenza vaccine (TIV)
Study: 16991077
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of trivalent inactivated influenza vaccine (TIV)
Study: 11444449
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 300 microg
Study: 7996111
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid (2 x 250 mg)
Study: 7996111
Drug: Acetaminophen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (2 x 250 mg)
Study: 7996111
Drug: Ibuprofen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2 x 250 mg)
Study: 7996111
Drug: Ketoprofen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (2 x 250 mg)
Study: 7996111
Drug: Acetaminophen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (2 x 250 mg) plus codeine (2 x 250 mg)
Study: 7996111
Drug: Penicillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (2 x 250 mg)
Study: 7996111
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (2 x 250 mg)
Study: 7996111
Drug: Penicillin plus
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin plus ibuprofen (2 x 250 mg)
Study: 7996111
Drug: Methylprednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (2 x 250 mg) plus penicillin (2 x 250 mg)
Study: 31957958
Drug: Anhydrous gel
Normalized name: SiloMac Anhydrous Gel
DrugBank: Sodium sulfate (DB09472)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anhydrous gel with TriHex peptides
Study: 29746713
Drug: SCY-078 (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCY-078 (1250 mg loading dose on day 1 followed by 750 mg once daily for 7 days)
Study: 29746713
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg single oral dose)
Study: 24568171
Drug: In-office light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office light plus 25 percent hydrogen-peroxide whitening gel treatment (In-office group)
Study: 18272931
Drug: 1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/d GPLC
Study: 18272931
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d GPLC
Study: 18772447
Drug: Low-dose rt-PA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rt-PA (0.3 mg/kg or 0.45 mg/kg) plus eptifibatide (75 microg/kg bolus followed by 0.75 microg/kg per min infusion for 2 hours)
Study: 18772447
Drug: Standard-dose rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose rt-PA (0.9 mg/kg)
Study: 18772447
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment group (low-dose rt-PA plus eptifibatide)
Study: 18772447
Drug: Standard-dose rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose rt-PA group
Study: 30293364
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment group
Study: 15889948
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg/day, N = 370)
Study: 15889948
Drug: Olanzapine/fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/fluoxetine combination (6/25, 6/50, or 12/50 mg/day; N = 86)
Study: 12534412
Drug: Nitazoxanide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (100 mg b.d. for age 2-3 years; 200 mg b.d. for age 4-11 years; 500 mg b.d. for age > 12 years)
Study: 10818026
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control policy with a sulphonylurea or insulin
Study: 8679354
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lignocaine-prilocaine) applied for 8 hours after burn injury
Study: 8679354
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment applied to contralateral leg
Study: 8679354
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lignocaine-prilocaine)
Study: 7049583
Drug: Chlormezanone 200
Normalized name: chlormezanone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormezanone 200 mg
Study: 30445896
Drug: Cabotegravir LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir LA 800 mg every 12 weeks after 4 weeks of oral cabotegravir 30 mg
Study: 30445896
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) every 12 weeks after 4 weeks of placebo tablets
Study: 19641353
Drug: Standard RRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard RRP without suspension operation (group 2)
Study: 17656420
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D 800 iu plus calcium 1,200 mg
Study: 17656420
Drug: Daily calcium
Normalized name: Calcium Carbonate/Vitamin D 600 MG-125 IU Oral Tablet [DAILY CALCIUM + VITAMIN D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calcium 1,200 mg (Control)
Study: 16306204
Drug: AA1.5 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA1.5 (1.5 g/kg/d for 20 h followed by 3.0 g/kg/d for 5 h)
Study: 16306204
Drug: AA3.0 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA3.0 (3.0 g/kg/d for 20 h followed by 1.5 g/kg/d for 5 h)
Study: 16306204
Drug: AA-Ext (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-Ext (1.5 g/kg/d for 20 h followed by 3.0 g/kg/d for 20 h)
Study: 10832809
Drug: Verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (5 mg i.v. + 2 microg/kg/min over 24 hours)
Study: 3318754
Drug: Individual supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual supportive therapy
Study: 14872504
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg three times daily
Study: 3901756
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 or 500 mg three times daily
Study: 30504928
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.5 mg/kg, iv
Study: 27102820
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine (CYD-TDV)
Study: 24112594
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum for at least 20 minutes every 2 hours starting at the time of capsule ingestion
Study: 22144722
Drug: Thermal mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal mineral water at 38°C for three weeks, five times a week for 20 minutes a day plus magnetotherapy three times weekly.
Study: 22144722
Drug: Thermal mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal mineral water at 36°C for three weeks, five times a week for 20 minutes a day plus magnetotherapy three times weekly.
Study: 20816153
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of satisfaction between treatment groups
Study: 18446090
Drug: High daily
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High daily dose of soy isoflavones (900 mg/day)
Study: 16181368
Drug: TACE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE with doxorubicin (20-60 mg) and lipiodol (2-20 mL)
Study: 14600448
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL nonionic contrast material (300 mgI/mL) pushed with 40 mL saline solution
Study: 14600448
Drug: 120 mL
Normalized name: 120 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mL nonionic contrast material (300 mgI/mL) alone
Study: 10386508
Drug: Warfarin sodium,
Normalized name: Warfarin Sodium, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin sodium, 1.25 mg/d
Study: 10386508
Drug: Warfarin sodium,
Normalized name: Warfarin Sodium, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin sodium, 1.25 mg/d plus aspirin, 300 mg/d
Study: 10386508
Drug: Aspirin, 300
Normalized name: Aspirin, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 300 mg/d
Study: 10386508
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin therapy aiming at INR of 2.0 to 3.0
Study: 8698374
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 g oral azithromycin
Study: 8698374
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg twice daily for seven days
Study: 1898642
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (5 micrograms/kg/min i.v.)
Study: 25335326
Drug: Qizhi Jiangtang
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qizhi Jiangtang Capsule (QJC), 5 pills per time, 3 times a day
Study: 25335326
Drug: Valsartan Capsule
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan Capsule 160 mg, once daily
Study: 25335326
Drug: Qizhi Jiangtang
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qizhi Jiangtang Capsule (QJC)
Study: 18596517
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with fenestration tubes
Study: 15752839
Drug: ALVAC-HIV (vCP1521)/AIDSVAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV (vCP1521)/AIDSVAX B/E gp120 prime-boost vaccine
Study: 8556996
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg kg‐1 rocuronium in obese patients
Study: 8556996
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg kg‐1 rocuronium in all groups
Study: 1991925
Drug: Serum PPL-specific
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PPL-specific IgE antibodies
Study: 1991925
Drug: Serum PPL-specific
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PPL-specific IgG antibodies
Study: 6173900
Drug: Exogenous leukocyte
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous leukocyte interferon therapy as adjuvant treatment
Study: 26977626
Drug: Mexidol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (1000 mg/day for 14-15 days)
Study: 24813928
Drug: Intervention of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention of antibiotic prescription recommendations evaluated on the third day by an infectious disease specialist.
Study: 24813928
Drug: Intervention of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention of antibiotic prescription recommendations with dose adjustment or change of route.
Study: 24813928
Drug: Intervention of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention of antibiotic prescription recommendations that were personally commented on.
Study: 24813928
Drug: Intervention of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention of antibiotic prescription recommendations overall.
Study: 21988468
Drug: Ceftazidime continuous
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime continuous infusion (4g after 2g loading dose for MDRD 10-30 ml/min, 6g for MDRD 40-80 ml/min, 8g for MDRD 90-110 ml/min, 10g for MDRD 120-190 ml/min, 12g/day for MDRD >200 ml/min)
Study: 21988468
Drug: Ceftazidime continuous
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime continuous infusion
Study: 1457267
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg as capsules) and soluble paracetamol (1 g)
Study: 1457267
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg as capsules)
Study: 6379120
Drug: Full dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dosage daunorubicin, cytosine arabinoside, and 6-thioguanine (F DAT)
Study: 6379120
Drug: Attenuated dosage
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated dosage daunorubicin, cytosine arabinoside, and 6-thioguanine (At DAT)
Study: 20089522
Drug: Dienogest (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest (2 mg/day, orally)
Study: 18653184
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin acetate (900 microg/day, intranasally)
Study: 11497535
Drug: Conjugated estrogens,
Normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days (n = 45)
Study: 9504447
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy with participant selected diet
Study: 8040666
Drug: CT/RT (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT/RT (chemotherapy with radiotherapy)
Study: 28646887
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (tPA) 4 mg followed by dornase alfa 5 mg, administered once daily for 3 days.
Study: 28646887
Drug: Placebo (tPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tPA 4 mg followed by normal saline), administered once daily for 3 days.
Study: 24249853
Drug: Advanced pharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced pharmacy practice experience (APPE) in medication therapy management (MTM)
Study: 17333792
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg, once daily for 5 days)
Study: 17333792
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg, 3 times a day for 5 days)
Study: 11566458
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg orally every 12 hours for 5 days)
Study: 9036746
Drug: Standard-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose heparin (100 U/kg bolus)
Study: 9036746
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (70 U/kg bolus)
Study: 9036746
Drug: Early sheath
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early sheath removal (heparin stopped after procedure)
Study: 9036746
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-dose heparin and early sheath removal
Study: 9036746
Drug: Late sheath
Normalized name: SHEATH,LATEX LARGE UROCARE #500335
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late sheath removal (heparin continued for 12 hours)
Study: 8342759
Drug: Fixed CPB
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed CPB flow of 2.4 l.m-2
Study: 3296129
Drug: Oral thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thromboxane synthetase inhibitor (TSI)
Study: 30392388
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (4-month concurrent training, 3 days/week, 60 min/session)
Study: 26621631
Drug: BB-12 given
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BB-12 given in capsule form
Study: 22075942
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg DIM daily for 6 months
Study: 17621671
Drug: Reduced-dose sirolimus-eluting
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reduced-dose sirolimus-eluting stents (SESs)
Study: 11982448
Drug: Olanzapine 7.5
Normalized name: olanzapine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 7.5 mg
Study: 11982448
Drug: Olanzapine 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10.0 mg
Study: 11982448
Drug: Haloperidol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 7.5 mg
Study: 10596656
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic ointment of Xylocaine 5%
Study: 15714749
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of anticoagulants with antiplatelet agents with rheological effects (piracetam, buflomedil, pentoxifylline)
Study: 15714749
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of anticoagulants with dipyridamole (antiplatelet agent without rheological effects)
Study: 2065391
Drug: JWYY tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: JWYY tablets
Study: 675836
Drug: Topical diethylcarbamazine
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical diethylcarbamazine citrate (DEC) applied daily
Study: 675836
Drug: Weekly topical
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly topical applications of DEC emulsion
Study: 675836
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of diethylcarbamazine citrate (DEC)
Study: 31818845
Drug: Intraperitoneal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal irinotecan added to standard systemic therapy (5-fluorouracil/leucovorin with oxaliplatin and bevacizumab)
Study: 31818845
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy (5-fluorouracil/leucovorin with oxaliplatin and bevacizumab)
Study: 28994364
Drug: Sildenafil (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (1-3 mg/kg/day every 8 hours)
Study: 28994364
Drug: Tadalafil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (1 mg/kg once a day)
Study: 26125945
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered trimethoprim-sulfamethoxazole (TSM)
Study: 26125945
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered cefuroxime and metronidazole (CXM)
Study: 16900802
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of prednisone daily for 5 consecutive days before the operation
Study: 7729788
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of oral DEX
Study: 7041450
Drug: Extra-amniotic prostaglandin
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic prostaglandin E2 gel
Study: 7041450
Drug: Amniotomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotomy with or without intravenous oxytocin
Study: 7041450
Drug: Extra-amniotic PGE2
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic PGE2 gel plus an indwelling catheter
Study: 27633250
Drug: Sembragiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sembragiline (1 mg daily)